Progress of non-small-cell lung cancer with ROS1 rearrangement
ROS1 rearrangement is found in 0.9%–2.6% of people with non-small-cell lung cancers (NSCLCs). Tyrosine kinase inhibitors (TKIs) target ROS1 and can block tumor growth and provide clinical benefits to patients. This review summarizes the current knowledge on ROS1 rearrangements in NSCLCs, including t...
Main Authors: | Xin Yang, Zhe Tang, Jing Li, Jizong Jiang, Yue Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-12-01
|
Series: | Frontiers in Molecular Biosciences |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1238093/full |
Similar Items
-
TARGETED THERAPY OF LUNG CANCER WITH THE ROS1 REARRANGEMENT
by: K. K. LAKTIONOV, et al.
Published: (2017-06-01) -
ROS1-Rearranged Lung Adenocarcinoma: From Molecular Genetics to Target Therapy
by: Ugo Testa, et al.
Published: (2023-08-01) -
Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene
rearrangement – case report and review of current therapeutic options
by: Julia Barbara Bargieł, et al.
Published: (2021-09-01) -
Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports
by: Lionel Michaux, et al.
Published: (2023-06-01) -
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
by: Laura Fabbri, et al.
Published: (2023-12-01)